Act to Ban Zohydro
Official title: To withdraw approval for the drug Zohydro ER and prohibit the Food and Drug Administration from approving such drug unless it is reformulated to prevent abuse.
Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.
Referred to the Subcommittee on Health.
Act to Ban Zohydro - Ends the sale and distribution of pure hydrocodone bitartrate extended-release capsules (marketed as Zohydro ER) within 45 days by withdrawing approval for its new drug application. Prohibits the Commissioner of Food and Drugs (FDA) from approving any new drug application for the capsules unless they are formulated to prevent abuse.
- Introduced in House Formatted Text PDF Formatted XML
Cite this page
U.S. Congress. (2026). H.R. 4241: Act to Ban Zohydro. 113th Congress. Open America. https://openamerica.io/bill/113-HR-4241/
"H.R. 4241: Act to Ban Zohydro." 113th Congress, 2026, Open America, https://openamerica.io/bill/113-HR-4241/.
H.R. 4241, 113th Cong. (2026), https://openamerica.io/bill/113-HR-4241/.
[H.R. 4241: Act to Ban Zohydro](https://openamerica.io/bill/113-HR-4241/)